All Pharma News
BlackThorn Advances Phase 2 Clinical Development for Selective KOR Antagonist

BlackThorn Advances Phase 2 Clinical Development for Selective KOR Antagonist
BIO SPACE
23 Jan 2020
Share Share
Polaris Partners — maps $400M for ninth fund

Polaris Partners — maps $400M for ninth fund
Natalie Grover ENDPTS
20 Jun 2019
Share Share
BlackThorn bags $76M to push targeted treatments for brain disorders

BlackThorn bags $76M to push targeted treatments for brain disorders
Amirah Al Idrus FIERCE BIOTECH
13 Jun 2019
Share Share
BlackThorn Announces Positive Ph 1 Results KOR Antagonist, BTRX-335140

BlackThorn Announces Positive Ph 1 Results KOR Antagonist, BTRX-335140
BUSINESSWIRE
01 Apr 2019
Share Share
Biomatics raises $300M for healthcare fund, recruits biopharma veterans

Biomatics raises $300M for healthcare fund, recruits biopharma veterans
Amirah Al Idrus FIERCE BIOTECH
08 Nov 2018
Share Share
BlackThorn Therapeutics Names Bill Martin, Ph.D., President and Chief Operating Officer

BlackThorn Therapeutics Names Bill Martin, Ph.D., President and Chief Operating Officer
BUSINESSWIRE
08 Nov 2018
Share Share
Jnana President Joanne Kotz to take on CEO role

Jnana President Joanne Kotz to take on CEO role
Conor Hale FIERCE BIOTECH
07 Nov 2018
Share Share
BlackThorn Announces Exclusive Licensing Agreement & Yale University

BlackThorn Announces Exclusive Licensing Agreement & Yale University
PRESS RELEASE
06 Aug 2018
Share Share
BlackThorn Therapeutics Names George S. Golumbeski, Ph.D., to Board of Directors

BlackThorn Therapeutics Names George S. Golumbeski, Ph.D., to Board of Directors
PRESS RELEASE
12 Jun 2018
Share Share
BlackThorn Initiates Ph1 Study of BTRX-335140, Investigational (KOR) Antagonist

BlackThorn Initiates Ph1 Study of BTRX-335140, Investigational (KOR) Antagonist
PRESS RELEASE
06 Jun 2018
Share Share